Checkpoint Inhibitors news and latest updates

In Depth 19 Mar 2025

Breast cancer treatments heat up: Five therapies poised to transform patient outcomes

Find out more about the overall breast cancer treatment landscape, as biotech companies make progress with different approaches.

March 19, 2025 - 11 minutesmins - By Willow Shah-Neville

In Depth 12 Mar 2025

Checkpoint inhibitors in cancer: breakthroughs, setbacks, and what’s next

Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.

March 12, 2025 - 10 minutesmins - By Roohi Mariam Peter

In Depth 17 Jan 2025

Are PD-1 and PD-L1 checkpoint inhibitors as good as we thought?

Checkpoint inhibitors, especially those targeting PD-1 and PD-L1, are exploding in popularity. But how much of it is hype?

January 17, 2025 - 7 minutesmins - By Roohi Mariam Peter

In Depth 11 Dec 2024

Targeting sugar molecules: Can glycobiology lead to a new era for cancer immunotherapy?

Find out more about the emerging field of glycobiology, which could potentially lead to a new type of cancer immunotherapy.

December 11, 2024 - 9 minutesmins - By Willow Shah-Neville

News and Trends 4 Sep 2024

2024: a year of breakthroughs for endometrial cancer?

New treatments have been approved by regulators for endometrial cancer, which are regarded as major therapeutic breakthroughs.

September 4, 2024 - 7 minutesmins - By Roohi Mariam Peter

News and Trends 27 Aug 2024

Could microbiome drugs be the key to unlocking checkpoint inhibitors’ potential?

As Microbiotica announces phase 1 approval for two microbiome drugs we delve into their potential in oncology and beyond.

August 27, 2024 - 11 minutesmins - By Jules Adam

News and Trends 15 Jun 2023

IOME Bio claims breakthrough in cancer research

IOME Bio, a French seed stage biotechnology company focused on overcoming tumor resistance to immune checkpoint inhibition, has published its foundational research by founders Arlene Sharpe and Dennis Kasper in Nature. The company said its work reveals unique insights into the critical importance of the RGMb/PD-L2 pathway in immunotherapy resistance and further strengthens the significance […]

June 15, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 3 Mar 2023

Orphan drug designation for Laevoroc metabolic immune checkpoint inhibitor

Laevoroc Immunology, a privately-owned, Swiss oncology development company, has announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for immune checkpoint inhibitor LR 09. LR 09 is a novel metabolic immune checkpoint inhibitor, for the treatment of patients with hematological malignancies who are diagnosed with a relapse after allogeneic stem […]

March 3, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 1 Feb 2023

Next-generation small molecules hold promise for immunotherapy

By Ian B. Walters, chief executive officer and chairman, Portage Biotech In recent years, PD-1/PD-L1 checkpoint antibody therapies have revolutionized the immuno-oncology landscape and offered cancer patients the hope for a long term treatment and cure of their disease. While these treatments have shown great promise in reversing T-cell exhaustion, many patients still have limited […]

February 1, 2023 - 3 minutesmins - By External Contributor

News and Trends 20 Jan 2023

DeuterOncology closes financing round to start lung cancer study

DeuterOncology, a clinical-stage drug development company, has closed €5.65 million ($6.1 million) series A financing, to start the phase I clinical study for its lead product DO-2, an improved MET kinase inhibitor currently being developed as a potential best-in-class targeted therapy for lung cancer. The financing included participation from historical investor Newton Biocapital and new […]

January 20, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 14 Dec 2022

ImaginAb launches trial to study neoadjuvant immunotherapy

ImaginAb Inc., in collaboration with Memorial Sloan Kettering Cancer Center (MSK) and Melanoma Research Alliance (MRA), has launched an investigator-initiated phase II trial. It will explore the efficacy and safety of neoadjuvant immune checkpoint inhibitor treatment of stage III surgically resectable melanoma through use of CD8 ImmunoPET. ImaginAb is a global biotechnology company focused on […]

December 14, 2022 - 2 minutesmins - By Jim Cornall

immutep checkpoint inhibitor lag 3 cancer

Interview 29 Nov 2022

LAG-3: The next big checkpoint inhibitor target

Since their first approval a decade ago, immune checkpoint inhibitors have been gaining momentum in the treatment of cancer. The Australian-French firm Immutep explains why the immune checkpoint target LAG-3 is ripe for innovation in the space. Immune checkpoint inhibitors have revolutionized the field of immuno-oncology in the last decade, especially since the approval of […]

November 29, 2022 - 7 minutesmins - By Jonathan Smith

Resources

Categories

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Checkpoint Inhibitors

Breast cancer treatments heat up: Five therapies poised to transform patient outcomes

Checkpoint inhibitors in cancer: breakthroughs, setbacks, and what’s next

Are PD-1 and PD-L1 checkpoint inhibitors as good as we thought?

Targeting sugar molecules: Can glycobiology lead to a new era for cancer immunotherapy?

2024: a year of breakthroughs for endometrial cancer?

Could microbiome drugs be the key to unlocking checkpoint inhibitors’ potential?

IOME Bio claims breakthrough in cancer research

Orphan drug designation for Laevoroc metabolic immune checkpoint inhibitor

Next-generation small molecules hold promise for immunotherapy

DeuterOncology closes financing round to start lung cancer study

ImaginAb launches trial to study neoadjuvant immunotherapy

LAG-3: The next big checkpoint inhibitor target

Subscribe to our newsletter to get the latest biotech news!

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!